Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Oxaliplatin 3Leucovorin 3Gemcitabine 3Fluorouracil 3Bevacizumab 3trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2dabrafenib 2copanlisib 2abiraterone 2Vorinostat 2Sunitinib 2Specimen Handling 2Sorafenib 2Nivolumab 2Immunoglobulin G 2HhAntag691 2Disulfides 2Dasatinib 2Capecitabine 2Bortezomib 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2venetoclax 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × cediranib × Plasma cell × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡